ArticleVaccines2023
Therapeutic Cancer Vaccines and Their Future Implications.
Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Vaxjo 2.0: An ontology- and large language model-powered knowledge base of vaccine adjuvants and mechanisms.Frontiers in cellular and infection microbiology · 2026Article
- RMAD1, a Novel Cell-Penetrating Peptide Derived from ADARB2: Preclinical Insights into Antigen Uptake and T Cell Activation.International journal of biological sciences · 2026Article
- The search for a TNBC vaccine: the guardian vaccine.Cancer biology & therapy · 2025Review
- In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity.Vaccines · 2025Article
- Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy.Molecular biotechnology · 2025Review
- Advances and challenges in cancer immunotherapy: mechanisms, clinical applications, and future directions.Frontiers in pharmacology · 2025Review
- Unlocking cancer vaccine potential: What are the key factors?Human vaccines & immunotherapeutics · 2024Review
- Prophylactic and therapeutic vaccine development: advancements and challenges.Molecular biomedicine · 2024Review
- CanVaxKB: a web-based cancer vaccine knowledgebase.NAR cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continuous progress in vaccine development witnessed in the last decades, culminated with the development of vaccines against cancers, is set to change how various cancers are treated [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.